 |
|
|
| |
Effectiveness of Daclatasvir-Based Therapy in Patients With Chronic
Hepatitis C in Europe: Experience From the Named Patient Program
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
The International Liver Congress™ 2016 The 51st Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 13-17, 2016
Weis N,1 Young J,2 Hofer H,3 Irving W,4 Weiland O,5 Giostra E,6 Pascasio JM,7 Castells L,8 Prieto M,9 Lefevre C,10 Evans D,10 Bucher HC,2 Calleja JL11
1Copenhagen University Hospital, Hvidovre, Denmark; 2Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland; 3Medical University of Vienna, Vienna, Austria; 4NIHR Nottingham Digestive Diseases Biomedical Research Unit, University of Nottingham, Nottingham UK; 5Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden; 6University Hospitals of Geneva, Geneva, Switzerland ; 7 University Hospital of Virgen del Rocio, Sevilla, Spain; 8Hospital General Vall Hebron, Barcelona, Spain; 9Hospital La Fe, Valencia, Spain; 10Bristol-Myers Squibb, Rueil-Malmaison, France; 11 Hospital Universitario Puerta Hierro Majadahonda, Madrid, Spain.
Daclatasvir Active in GT 5 & 6.....http://www.natap.org/2015/HCV/091715_06.htm
|
| |
|
|
|
|
|
